Q-omics provides the consensus-scored KRT8P17 profile across patient tissues and cancer cell-line models. KRT8P17 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, KRT8P17 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, KRT8P17 RNA expression shows 8,365 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight PAAD, BRCA, and ESCA as cancer lineages where KRT8P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P17 survival associations across molecular data types. KRT8P17 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P17 RNA expression–survival associations across cancer types. High KRT8P17 expression shows unfavorable associations in PAAD, GBM, KICH and UVM, but favorable associations in BLCA and CESC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for KRT8P17 RNA expression.
This table summarizes KRT8P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P17 shows higher tumor expression in BRCA, STAD, KIRP, HNSC, LUAD and PRAD. The BRCA box plot shows higher KRT8P17 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p < 0.001).
This table shows molecular features associated with KRT8P17 in patient tissues and cancer cell lines. In patient samples, KRT8P17 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
